IRBM SPA

Their core work

IRBM is an Italian private drug discovery and development company based near Rome. Their H2020 project portfolio reveals expertise in medicinal chemistry, peptide-drug conjugates for cancer therapy, halogenated reagent chemistry, and pharmacological approaches to skeletal disorders. They operate as an SME contributing specialized pharmaceutical chemistry and biological screening capabilities to international research consortia, bridging academic research and commercial drug development.

What they specialise in

How they've shifted over time

IRBM's early H2020 participation (2015-2018) centered on chemistry-driven drug delivery — peptide conjugates for cancer and novel halogenated reagent development. By 2021, their focus shifted toward pharmacological mechanisms, specifically autophagy modulation for skeletal disease. This suggests a broadening from pure synthetic chemistry services toward more target-driven pharmacology and therapeutic development.

IRBM appears to be moving from chemical synthesis support roles toward mechanism-based drug discovery, which could make them a more strategic partner in translational health projects.

How they like to work

IRBM has never coordinated an H2020 project, consistently participating as a partner or third party in research-excellence programs (MSCA and ERC). With 17 unique partners across 7 countries from just 3 projects, they join relatively large, internationally diverse consortia. This profile suggests a specialist contributor that provides specific technical capabilities — likely compound synthesis, screening, or assay development — rather than driving project strategy.

Despite only 3 projects, IRBM has built connections with 17 distinct partners across 7 countries, indicating they join well-connected multinational consortia typical of MSCA and ERC programs.

What sets them apart

IRBM brings private-sector drug discovery infrastructure to academic-led EU projects — a relatively rare profile among MSCA and ERC participants, which are dominated by universities and public research institutes. As an SME with hands-on pharmaceutical chemistry capabilities, they can offer industry-grade compound libraries, screening platforms, and translational know-how that academic partners typically lack. This makes them particularly valuable for projects needing to move discoveries closer to clinical or commercial reality.

Highlights from their portfolio

• MAGICBULLET
  Addresses the high-value area of targeted cancer drug delivery through peptide-drug conjugates — directly relevant to precision oncology trends.
• RE-STORE
  Most recent project (2021-2022) and an ERC Proof of Concept, suggesting this work aims to translate fundamental autophagy research into a viable therapeutic — a strong commercialization signal.